National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Semaglutide (Wegovy®). HTA ID: 22029

Semaglutide (Wegovy®) is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of ≥30 kg/m2 (obesity), or ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity e.g. dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.

 

NCPE Assessment Process Complete
Rapid review commissioned 09/05/2022
Rapid review completed 09/06/2022
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of semaglutide (Wegovy®) compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.